A systems biology approach to identifying drug targets and predicting therapeutic outcomes in myelodysplasia and acute myeloid leukaemia

Dr Pimanda will present results from a body of work using functional genomics to develop tools to predict drug response in Myelodysplasia (MDS), identify alternate treatment options for patients who fail current treatment and characterise treatment related changes to the sub-clonal architecture and function of dysplastic haematopoietic stem/progenitor cells (HSPCs). He will also present an integrative analysis of long intergenic non-coding RNA (lincRNAs) expression from 922 acute myeloid leukemia patients. These analyses show that leukemic and normal hematopoietic cell subsets express distinct lincRNAs and that gene signatures composed of as few as three lincRNA genes are independent predictors of clinical outcome across multiple patient cohorts.